Results 11 to 20 of about 35,072 (188)

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.

New England Journal of Medicine, 2021
BACKGROUND The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to ...
I. McInnes, Jaclyn K Anderson, M. Magrey, J. Merola, Yi Liu, M. Kishimoto, S. Jeka, C. Pacheco-Tena, Xin Wang, Liang Chen, P. Zueger, John Liu, A. Pangan, F. Behrens   +13 more
semanticscholar   +1 more source

Adalimumab in conjunction with surgery compared with adalimumab monotherapy for Hidradenitis Suppurativa; a randomized controlled trial in a real-world setting.

Journal of American Academy of Dermatology, 2023
BACKGROUND Adalimumab, the only biologic registered for hidradenitis suppurativa (HS), shows clinical response in up to 60% of patients, leaving many patients in need for other treatment options such as surgery.
MD Pim Aarts, MD Johanna C. van Huijstee, MD Hessel H. van der Zee, Martijn B. A. van Doorn PhD, Kelsey R. van Straalen PhD, PhD Errol P. Prens   +5 more
semanticscholar   +1 more source

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Clinical, Cosmetic and Investigational Dermatology, 2023
To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition.
F. Martora, M. Megna, T. Battista, L. Potestio, M. C. Annunziata, C. Marasca, A. Villani, G. Fabbrocini   +7 more
semanticscholar   +1 more source

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

Journal of the European Academy of Dermatology and Venereology, 2023
Many national guidelines at the European level recommend first‐line therapy based on the anti‐TNF‐alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons.
L. Mastorino, S. Susca, C. Cariti, N. Sliquini, A. Verrone, E. Stroppiana, M. Ortoncelli, P. Dapavo, S. Ribero, P. Quaglino   +9 more
semanticscholar   +1 more source

Bimekizumab versus Adalimumab in Plaque Psoriasis.

New England Journal of Medicine, 2021
BACKGROUND Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to-severe
R. Warren, A. Blauvelt, J. Bagel, K. Papp, P. Yamauchi, A. Armstrong, R. Langley, V. Vanvoorden, D. de Cuyper, C. Cioffi, L. Peterson, N. Cross, K. Reich   +12 more
semanticscholar   +1 more source

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Rheumatology, 2023
Objectives To explore associations between serum adalimumab level, treatment response and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of adalimumab.
I. Jyssum, J. Gehin, Joseph Sexton, E. Kristianslund, Y. Hu, D. J. Warren, T. Kvien, E. Haavardsholm, S. W. Syversen, N. Bolstad, G. Goll   +10 more
semanticscholar   +1 more source

Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study

Gut and Liver, 2020
Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the Asan Medical Center ...
Eun Hye Oh, Jeongseok Kim, Namseok Ham, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye   +9 more
doaj   +1 more source

Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review

Respiratory Medicine Case Reports, 2022
Background: Tumor necrosis factor (TNF) inhibitors have been used in the treatment of cardiac sarcoidosis, infliximab being the most commonly used.
Jaleel Jerry G. Sweis, Nabil William G. Sweis, Christian Ascoli, Benjamin Levin, Boaz Avitall, Israel Rubinstein, George Kondos, Daniel A. Culver, Marc Judson, Robert Baughman, Dawood Darbar, Wonder Drake, Shiva Shahrara, Leslie T. Cooper, Jr., Nadera J. Sweiss   +14 more
doaj   +1 more source

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

RMD Open, 2022
Objectives To assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in the ongoing long-term extension (LTE) of SELECT-COMPARE, a randomised controlled phase 3 trial of patients with active ...
R. Fleischmann, E. Mysler, L. Bessette, C. Peterfy, P. Durez, Yoshiya Tanaka, J. Świerkot, N. Khan, X. Bu, Yihan Li, I. Song   +10 more
semanticscholar   +1 more source

Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.

Gastroenterology, 2022
BACKGROUND & AIMS Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. SERENE CD evaluated higher vs standard adalimumab induction dosing and clinically adjusted (CA) vs therapeutic drug monitoring (TDM ...
G. D'Haens, W. Sandborn, E. Loftus, S. Hanauer, S. Schreiber, L. Peyrin-Biroulet, R. Panaccione, J. Panés, F. Baert, J. Colombel, M. Ferrante, E. Louis, A. Armuzzi, Qian Zhou, V. Goteti, N. Mostafa, T. Doan, J. Petersson, T. Finney-Hayward, A. Song, A. Robinson, S. Danese   +21 more
semanticscholar   +1 more source